MedTrace Logo

Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells

NCT05017298 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-02-07

No results posted yet for this study

Summary

This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.

Conditions

  • Corona Virus Infection
  • Covid19

Interventions

BIOLOGICAL

Allogeneic adipose-derived stem cells

Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue

Sponsors & Collaborators

  • Celltex Therapeutics Corporation

    lead INDUSTRY

Principal Investigators

  • Derek W Guillory, MD · Root Causes Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2024-11-01
Completion
2026-11-15
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05017298 on ClinicalTrials.gov